All In Biotech

Drug Trial Radar · NCT05729074

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients

A Randomized, Placebo/Active Controlled, Single/Multiple Dosing, Dose Escalation Clinical Phase 1a/b Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

81

Actual

Start

Feb 13, 2023

Primary completion

Sep 20, 2024

Study completion Sep 20, 2024

Sponsor

Lead sponsor
HK inno.N CorporationIndustry
Sponsor type
Industry
First posted
Feb 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 19 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety, tolerability and pharmacokinetic properties of IN-A002 Ointment in healthy adult male volunteers and mild to moderate atopic dermatitis patients

Conditions

  • Mild to Moderate Atopic Dermatitis

Interventions

  • IN-A002 Ointment 0.3% or IN-A002 Placebo OintmentDrug

    Drug: IN-A002 Ointment 0.3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2

  • IN-A002 Ointment 0.5% or IN-A002 Placebo OintmentDrug

    Drug: IN-A002 Ointment 0.5%, 10 g/1000 cm2, for 1 day Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2, for 1 day

  • IN-A002 Ointment 1% or IN-A002 Placebo OintmentDrug

    Drug: IN-A002 Ointment 1%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2

  • IN-A002 Ointment 3% or IN-A002 Placebo OintmentDrug

    Drug: IN-A002 Ointment 3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2

  • IN-A002 Ointment 5% or IN-A002 Placebo OintmentDrug

    Drug: IN-A002 Ointment 5%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2

  • IN-A002 Ointment 1%Drug

    Drug: IN-A002 Ointment 1%, 3 g/1000 cm2

  • IN-A002 Ointment 3%Drug

    Drug: IN-A002 Ointment 3%, 3 g/1000 cm2

  • Elidel Cream 1% (pimecrolimus)Drug

    Drug: Elidel Cream 1% (pimecrolimus), 3 g/1000 cm2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventTime frame: Up to post study visit (Day 40)
  2. Physical examinationTime frame: Up to post study visit (Day 40)
  3. Clinical Laboratory TestTime frame: Up to post study visit (Day 40)
  4. Topical Reaction AssessmentTime frame: Predose(0h) at Day 1, Day 8, Day 15, and Day 22, Post-dose(0.5h) at Day 1, Day 8, Day 15, and Day 22, Day 28, Day 29(0h, 0.5h), PSV
  5. NRS (Numerical Pain Rating Scale)Time frame: Predose(0h) at Day 1, Day 8, Day 15, and Day 22, Post-dose(0.5h) at Day 1, Day 8, Day 15, and Day 22, Day 28, Day 29(0h, 0.5h), PSV
  6. EASI scoreTime frame: Day 1, Day 8, Day 15, Day 22, Day 29
  7. IGA scoreTime frame: Day 1, Day 8, Day 15, Day 22, Day 29
  8. Itch QuestionnaireTime frame: Day 1, Day 8, Day 15, Day 22, Day 29
  9. Dermatology Life Quality Index (DLQI)Time frame: Day 1, Day 8, Day 15, Day 22, Day 29

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chungbuk National University Hospital

    Cheongju-si, North Chungcheong, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.